22.05.2024 - Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that three submitted .
(0) TEPEZZA significantly improved the clinical course of Thyroid Eye Disease (TED) in all patient subgroups, including those with more severe disease at baseline For patients in the follow-up period with data available at 51 weeks after the last dose of TEPEZZA, 67 percent had a proptosis response, 69 percent had a diplopia response and 83 percent had an ophthalmic composite outcome response
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new pooled data from the TEPEZZA (teprotumumab-trbw) Phase 2 and Phase 3 clinical trials are now published in
The
Lancet Diabetes Endocrinology. The data further reinforce that TEPEZZA significantly improves proptosis (eye bulging) and diplopia (double vision) for TED patients in different subgroups, with most maintaining a long-term response. TEPEZZA the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for TED is a fully human monoclonal antibody (mAb) and a targeted inhibitor of the insu